August 24, 2020 - Biologics by McKesson was selected by Taiho Oncology, Inc. as a specialty pharmacy provider for INQOVI (decitabine and cedazuridine) tablets for the treatment of adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML), two blood malignancies. INQOVI, approved by the U.S. Food and Drug … [Read more...]
McKesson named to Diversity Best Practices Inclusion Index
August 18, 2020 - McKesson announced it was named to the Diversity Best Practices (DBP) fourth annual Inclusion Index. McKesson was among the 98 organizations that earned a top score and a place on the index. Launched in 2016, Diversity Best Practices is “the preeminent organization for mid to large size organizational diversity thought leaders to share best practices and … [Read more...]
McKesson expands partnership with U.S. government to distribute future COVID-19 vaccines
August 17, 2020 - McKesson Corporation announced it will expand its existing partnership with the Centers for Disease Control (CDC) to support the U.S. government’s Operation Warp Speed (OWS) team as a centralized distributor of future COVID-19 vaccines and ancillary supplies needed to administer vaccinations. Vaccines and related supplies will be delivered to point-of-care … [Read more...]
Supplylogix enhances Pinpoint Order software to help pharmacy customers better track inventory movement
August 11, 2020 - Supplylogix (Dallas, TX), a division of McKesson Corporation, announced the availability of the latest enhancement to the Pinpoint Order software. The new Inventory Segmentation feature expands on the existing functionality of Pinpoint Order, giving users a dashboard to view their medication categories, in groups of 10, and the associated inventory … [Read more...]
Quidel’s Sofia SARS Antigen FIA updates EUA performance data to 96.7% PPA vs PCR
July 20, 2020 – Quidel Corporation (San Diego, CA) announced it has updated the performance data for its Sofia SARS Antigen FIA test on its package insert to 96.7% using direct nasal swab specimens versus PCR as a result of further studies included in its amended Emergency Use Authorization (EUA) that were submitted to the U.S. Food and Drug Administration … [Read more...]
McKesson realigns organizational structure
McKesson Corporation announced changes to its reportable business structure. The company has revised its reportable segments commencing in the second quarter of fiscal 2021. Under the realignment, McKesson will have four reportable segments. The new reportable segments are: Medical-Surgical Solutions Led by Stanton McComb, presidentUnaffected by the … [Read more...]
XPOVIO (selinexor), FDA approved for treatment of relapsed or refractory diffuse large B-cell Lymphoma (DLBCL), available at Biologics by McKesson
Biologics by McKesson, an independent specialty pharmacy specializing in oncology, rare diseases and other complex therapeutic areas, was selected by Karyopharm Therapeutics, Inc. as a specialty pharmacy provider for XPOVIO (selinexor) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL), not otherwise specified, including … [Read more...]